ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

16,703Medicare Part D Prescriptions Filled, Including Refills

Rank: 22 out of 1448

$2.07M Total Retail Price of All Prescriptions

Rank: 8 out of 1448

524 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 524 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

7% of this provider’s 524 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Risky Drugs to Seniors

1% of this provider’s 15,484 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

58% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$124 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

32 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
BENICAR 1,097 1,052 10 1 50
LIVALO 969 926 10 2 154
EFFIENT 784 744 10 3 69
ATENOLOL 783 714 4 12
FUROSEMIDE 581 543 5 7
DIOVAN 517 498 6 15
GEMFIBROZIL 401 349 10 7 127
ULORIC 355 320 10 8 146
VOLTAREN 328 301 9 107
LOSARTAN POTASSIUM 323 293 10 11
AMLODIPINE BESYLATE 312 294 11 2
GLIMEPIRIDE 309 296 12 66
LIDODERM 304 283 13 81
SINGULAIR 295 279 14 91
AVODART 279 264 15 120
BRILINTA 276 276 10 16 222
NEXIUM 265 235 17 49
WELCHOL 249 232 18 103
PLAVIX 242 219 19 14
ISOSORBIDE MONONITRATE ER 237 224 20 16
VICTOZA 3-PAK 236 197 21 246
LEVOTHYROXINE SODIUM 229 223 22 21
MULTAQ 219 218 23 57
HYDRALAZINE HCL 215 195 24 44
SOTALOL 210 157 25 40
CLOPIDOGREL 203 191 26 10
ADVAIR DISKUS 202 188 27 74
CARVEDILOL 200 197 28 1
MONTELUKAST SODIUM 181 173 29 135
PANTOPRAZOLE SODIUM 169 162 30 42
ATORVASTATIN CALCIUM 164 137 31 4
TAMSULOSIN HCL 164 159 31 46
POTASSIUM CHLORIDE 161 145 33 19
OMEPRAZOLE 159 150 34 23
SUCRALFATE 149 135 35 220
METFORMIN HCL 145 132 36 25
TRIAMCINOLONE ACETONIDE 144 127 37 96
FLECTOR 135 120 38 242
LOVAZA 130 127 39 39
METOCLOPRAMIDE HCL 128 116 40 190
METOPROLOL TARTRATE 122 94 41 9
CYMBALTA 120 111 42 123
DILTIAZEM ER 118 114 43 78
FLECAINIDE ACETATE 108 105 44 53
CRESTOR 106 106 45 17
TRADJENTA 92 86 46 252
JANUVIA 88 86 47 64
LIPITOR 83 72 48 30
DEXILANT 81 74 49 87
AMOX TR-POTASSIUM CLAVULANATE 79 72 50 251
NOVOTWIST 78 65 10 51 342
PREDNISONE 75 70 52 110
LEVEMIR FLEXPEN 75 69 52 307
VERAPAMIL ER 74 58 54 88
AZOR 71 69 55 125
VICTOZA 2-PAK 70 60 56 349
PEN NEEDLE 68 59 57 173
FAMOTIDINE 67 67 58 60
ALENDRONATE SODIUM 59 59 59 41
NAMENDA 56 56 60 93
DONEPEZIL HCL 54 54 61 68
PROPAFENONE HCL 53 53 62 62
RANEXA 52 48 63 37
SURE COMFORT 51 43 64 240
PATANOL 51 50 64 175
MEGESTROL ACETATE 50 49 R 66 126
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 12, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.